How is chronic myelogenous leukemia (CML) staged?

Updated: May 23, 2021
  • Author: Emmanuel C Besa, MD; Chief Editor: Sara J Grethlein, MD, FACP  more...
  • Print

Staging of patients is based on several analyses using multiple variate analysis between the association of pretreatment host and leukemic cell characteristics and corresponding survival rates. The findings from these studies classify patients into the following groups:

  • Good risk (average survival of 5-6 years)

  • Intermediate risk (average survival of 3-4 years)

  • Poor risk (average survival of 2 years)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!